Jade Biosciences, Inc.
JBIONasdaq
$20.86
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↑ +136.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$893.9M
P/E
2.5
P/S
—
P/B
4.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$129.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-43.7%
ROIC
—
Debt / Equity
—
Net Cash
$311.3M
Return 1Y
+119.3%
Company profile
Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
- CEO
- Timothy P. Noyes
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Massachusetts
- Website
- aerovatetx.com
Management & directors
- Bekiroglu ElizabethSee Remarks
- Dahms Bradford D.Chief Financial Officer
- Frohlich TomChief Executive Officer
- King Andrew JamesSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
JBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.57↓ -95.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$8.9M | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$113.5M |
| Net income | -$9.6M | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127.4M |
| Diluted EPS | — | -$1.87 | -$2.10 | -$2.87 | -$2.44 | -$3.19 |
| Operating cash flow | -$7.9M | -$27.4M | -$39.1M | -$56.8M | -$71.2M | -$94.7M |
| Free cash flow | — | -$27.6M | -$39.3M | -$56.9M | — | -$94.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$26.2M | -$15.6M | -$20.0M | -$23.4M | -$27.8M | -$27.4M | -$35.0M | -$43.4M |
| Net income | -$24.8M | -$16.9M | -$30.1M | -$38.2M | -$32.1M | -$25.2M | -$31.9M | -$40.4M |
| Diluted EPS | -$0.86 | -$5.35 | -$9.54 | -$12.10 | -$0.86 | -$0.48 | $10.25 | -$0.57 |
| Operating cash flow | -$20.4M | -$6.8M | -$15.8M | -$18.8M | -$20.2M | -$22.1M | -$33.6M | -$24.1M |
| Free cash flow | — | — | — | — | — | -$22.2M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-12 | Dahms Bradford D.· Chief Financial Officer | Award | 37,813 | $0.00 | $0.00 | filing |
| 2026-02-12 | Bekiroglu Elizabeth· See Remarks | Award | 28,125 | $0.00 | $0.00 | filing |
| 2026-02-12 | Frohlich Tom· Chief Executive Officer | Award | 78,750 | $0.00 | $0.00 | filing |
| 2026-02-12 | King Andrew James· See Remarks | Award | 41,250 | $0.00 | $0.00 | filing |
| 2025-10-06 | Fairmount Funds Management LLC | Award | 1,333,126 | $9.14 | $12.2M | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.